Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Creative Medical Technology Ho - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CELZ
Nasdaq
8731
https://creativemedicaltechnology.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Creative Medical Technology Ho
Creative Medical Technology Holdings Provides Corporate Update
- Mar 27th, 2024 1:00 pm
Creative Medical Technology Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Mar 24th, 2024 1:26 pm
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
- Mar 7th, 2024 2:15 pm
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
- Mar 6th, 2024 12:00 pm
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
- Dec 20th, 2023 2:35 pm
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain
- Oct 10th, 2023 12:00 pm
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
- Sep 19th, 2023 12:00 pm
What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?
- Aug 24th, 2023 2:45 pm
Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update
- Jul 13th, 2023 1:00 pm
Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements
- Jun 28th, 2023 12:00 pm
Creative Medical Technology Announces $2 Million Share Repurchase Program
- Jun 12th, 2023 12:01 pm
Creative Medical Technology Holdings Announces Reverse Stock Split
- Jun 9th, 2023 4:30 pm
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform
- May 31st, 2023 12:00 pm
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development
- May 22nd, 2023 12:30 pm
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line
- May 18th, 2023 12:00 pm
Creative Medical Technology Holdings First Quarter 2023 Earnings: US$0.075 loss per share (vs US$0.18 loss in 1Q 2022)
- May 14th, 2023 12:13 pm
Scroll